A total of 1,600 candidates will take part in the study.
King Edward Memorial Hospital Parel, and BYL Nair Hospitals, Mumbai Central — have received approval from ICMR to start the trial.
Three covid vaccines are undergoing trials in India
The phase II and phase III clinical trial of COVID-19 vaccine developed by the University of Oxford is all set to start in India. Indian pharmaceutical major Serum Institute of India has initiated the process, according to report by news agency ANI.
The COVID-19 vaccine was developed by the Jenner Institute, a part of the Nuffield Department of Medicine at the University of Oxford. The formulation is backed by by AstraZeneca PLC, a British-Swedish pharmaceutical company. AstraZeneca joined hands with Indian vaccine maker Serum Institute of India to manufacture COVID-19 vaccine for low-and-middle income countries.
Earlier this month, Drugs Controller General of India gave nod to conduct advanced trials in India. "Phase 2/3 clinical trial will be observer-blind, randomised, controlled study to determine the safety and immunogenicity of Covishield (COVID-19 vaccine) in healthy Indian adults," according to the study design.
Pune based drug maker has selected 17 sites in India to conduct the trial. A total of 1,600 candidates will take part in the study.
These sites include — Andhra Medical College (Visakhapatnam), JSS Academy of Higher Education and Research, (Mysore), Seth G. S. Medical College and KEM Hospital (Mumbai), KEM Hospital Research Centre (Vadu), B J Medical College and Sassoon General Hospital (Pune), All India Institute Of Medical Sciences (Jodhpur), Rajendra Memorial Research Institute of Medical Sciences, (Patna), Institute of Community Medicine ( Madras), Post Graduate Institute of Medical Education & Research (PGIMER), Bharati Vidyapeeth Deemed University Medical College and Hospital (Pune), Jehangir Hospital ( Pune), AIIMS (Delhi), ICMR- Regional Medical Research Centre ( Gorakhpur), TN Medical College & BYL Nair Hospital (Mumbai), Mahatma Gandhi Institute of Medical Sciences (Sewagram) and Government Medical College (Nagpur).
Of 1,600 candidates, 400 participants will be part of the immunogenicity cohort and will be randomly assigned in a 3:1 ratio to receive either Covishield or Oxford/AZ-ChAdOx1 nCoV-19, respectively.The remaining 1,200 participants from safety cohort will be randomly assigned in a 3:1 ratio to receive either Covishield or Placebo, respectively, according to ANI.
Each participant will administer two doses in a gap of four weeks. First dose will be given on day one and second dose will be scheduled on day 29, according to the study design.
“After the completion of phase II trial, reports will be submitted to the Data Safety Monitoring Board, then to the Central Drugs Standard Control Organization for stage 3 of the trial," Dr Hemant Deshmukh, King Edward Memorial Hospital said.
Two civic-run hospitals in Mumbai — King Edward Memorial Hospital Parel, and BYL Nair Hospitals, Mumbai Central — have received approval from the Indian Council for Medical Research to start phase II and phase III clinical trial of COVID-19 vaccine developed by the University of Oxford. At present, Brihanmumbai Municipal Corporation (BMC) is looking for volunteers to participate in the trial.
Source - livemint
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.